Zurich Fabry study - prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA

European Journal of Neurology

Volumn 19, Issue 11, 2012, Pages 1421-1426

  Sarikaya, H ^a   Yilmaz, M ^a   Michael, N ^a   Miserez, A R ^b   Steinmann, B ^c   Baumgartner, R W ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Diagene Laboratories Inc   (Sweden)

^c Division of Metabolism   (Sweden)

Author keywords

Cerebrovascular diseases and cerebral circulation; Fabry disease; Glycogenoses; Inherited metabolic disorders; Ischaemic stroke

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; ARTICLE; BLOOD LEVEL; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SCREENING; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; ADULT; ALPHA-GALACTOSIDASE; FABRY DISEASE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PREVALENCE; STROKE; SWITZERLAND; YOUNG ADULT;

EID: 84867695549     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03737.x     Document Type: Article

References (21)

1. Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA 2000; 284: 2771-2775.
2. Putaala J, Metso AJ, Metso TM, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 2009; 40: 1195-1203.
3. Ferro JM, Massaro AR, Mas JL. Aetiological diagnosis of ischaemic stroke in young adults. Lancet Neurol 2010; 9: 1085-1096.
4. Rolfs A, Bottcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005; 366: 1794-1796.
5. Brouns R, Sheorajpanday R, Braxel E, et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 2007; 109: 479-484.
6. Baumgartner RW, Sidler C, Mosso M, Georgiadis D. Ischemic lacunar stroke in patients with and without potential mechanism other than small-artery disease. Stroke 2003; 34: 653-659.
7. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
8. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML. Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 1981; 112: 247-251.
9. Linthorst GE, Poorthuis BJ, Hollak CE. Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol 2008; 51: 2082; author reply 2082-2083.
10. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 2010; 47: 217-222.
11. Brouns R, Thijs V, Eyskens F, et al. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke 2010; 41: 863-868.
12. Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010; 41: 78-81.
13. Baptista MV, Ferreira S, Pinho EMT, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study-screening genetic conditions in Portuguese young stroke patients. Stroke 2010; 41: 431-436.
14. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 2003; 80: 307-314.
15. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 2003; 22: 486-492.
16. Gambarin FI, Disabella E, Narula J, et al. When should cardiologists suspect Anderson-Fabry disease? Am J Cardiol 2010; 106: 1492-1499.
17. Igarashi T, Sakuraba H, Suzuki Y. Activation of platelet function in Fabry's disease. Am J Hematol 1986; 22: 63-67.
18. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 2005; 84: 261-268.
19. Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol 2006; 5: 791-795.
20. Viana-Baptista M. Stroke and Fabry disease. J Neurol 2011; [Epub ahead of print].
21. Rolfs A, Martus P, Heuschmann PU, et al. Protocol and Methodology of the Stroke in Young Fabry Patients (sifap1) Study: a Prospective Multicenter European Study of 5, 024 Young Stroke Patients Aged 18-55 Years. Cerebrovasc Dis. 2011; 31: 253-262.